AntiviralsLipohypertrophy and acquired resistance: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2025年 / 2043卷 / 1期

关键词：

D O I：

10.1007/s40278-025-75331-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：50 / 50

相关论文

共 50 条

[1] SelpercatinibDevelopment of acquired resistance: 2 case reports
Reactions Weekly, 2021, 1849 (1) : 388 - 388
[2] AntifungalsRenal toxicity and acquired resistance: 2 case reports
Reactions Weekly, 2020, 1815 (1) : 35 - 35
[3] AntibacterialsLack of efficacy and acquired resistance: 2 case reports
Reactions Weekly, 2022, 1901 (1) : 63 - 63
[4] Glecaprevir/pibrentasvirSkin pruritus and acquired resistance: 2 case reports
Reactions Weekly, 2021, 1874 (1) : 119 - 119
[5] Moxifloxacin/rifampicinHepatitis and acquired resistance to rifampicin: 2 case reports
Reactions Weekly, 2018, 1683 (1) : 474 - 474
[6] Ganciclovir/valganciclovirNeutropenia, thrombocytopenia and acquired resistance: 2 case reports
Reactions Weekly, 2023, 1942 (1) : 135 - 135
[7] SotrovimabEmergence of acquired resistance: 4 case reports
Reactions Weekly, 2022, 1908 (1) : 509 - 509
[8] PembrolizumabPneumonitis and acquired resistance: 3 case reports
Reactions Weekly, 2021, 1879 (1) : 309 - 309
[9] IcotinibDevelopment of acquired icotinib resistance in lung adenocarcinoma: 2 case reports
Reactions Weekly, 2018, 1691 (1) : 155 - 155
[10] AntineoplasticsPneumonia, acquired drug resistance and lack of efficacy: 2 case reports
Reactions Weekly, 2023, 1946 (1) : 64 - 64

← 1 2 3 4 5 →